The document comes several days after the preliminary offering of Polpharma was greenlighted by the Financial Supervisory Authority on May 20. The Polish group wants to buy 100% of the Romanian drug maker’s share capital at a price of RON1.379 per share. The offering is handled by Banca Comerciala Romana.
The document also highlights Polpharma’s plan for the phase pending the completion of the offering. Once the relevant legal thresholds are reached, the Polish group intends to exercise its right to carry out a squeeze-out procedure in respect to the remaining minority shareholders and subsequently initiate the delisting of Biofarm shares from the regulated market of the Bucharest Stock Exchange.
Ahead of the offering launch, Biofarm shareholders will be convened for a general ordinary meeting scheduled for June 15-16, 2026 to vote on the distribution of a gross special dividend of RON0.140263 dividend. The proposed registration date is June 30, 2026 and payments would start from July 10, 2026. The total value of the special dividend tops RON138 million.
(English version by Catalina Apostoiu)